Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developi...
Q2 2026
Aug 11, 2026
Q1 2026
May 7, 2026
FY 2025
Mar 16, 2026
Q4 2025
Q3 2025
Nov 4, 2025